OPKO HEALTH, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.26 USD | +3.28% |
|
+2.44% | -16.56% |
Presenter SpeechUnknown Analyst (Analysts)Welcome, everyone. I'm [ Sinja Bhita ] with JPMorgan...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
OPKO Health, Inc. is a multinational biopharmaceutical and diagnostics company. The Company's diagnostics segment consists of the clinical laboratory operations of BioReference Health, LLC (BioReference), its point-of-care operations. Its pharmaceutical segment consists of the pharmaceutical operations in Chile, Mexico, Ireland, Israel, Spain, Ecuador, France, the United States, and its pharmaceutical research and development operations. Through BioReference, it operates specialized laboratory divisions, such as GenPath (Urology), GenPath (Oncology), and GenPath (Women's Health). It has two commercial stage pharmaceutical products and several pharmaceutical compounds and technologies in various stages of research and development for a range of indications and conditions, including Rayaldee, Rayaldee, Oxyntomodulin, Biologics, NGENLA Somatrogon, and Factor VIIa-CTP. It develops and manufactures specialty active pharmaceutical ingredients (APIs) through FineTech Pharmaceutical, Ltd.
Calendar
2024-05-05
- Q1 2024 Earnings Release (Projected)
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
1.26
USD
Average target price
4.25
USD
Spread / Average Target
+237.30%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -16.56% | 878M | |
| -17.89% | 8.25B | |
| +39.20% | 3.57B | |
| -39.11% | 2.46B | |
| -8.06% | 2.46B | |
| -7.35% | 2.38B | |
| -12.61% | 1.81B | |
| -19.01% | 1.55B | |
| -40.66% | 1.21B | |
| +7.56% | 1.11B |
- Stock Market
- Equities
- OPK Stock
- News OPKO Health, Inc.
- Transcript : OPKO Health, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-10-2024 03
